

Pharmaniaga Berhad (199801011581 (467709-M))

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the quarter ended 31 March 2020	Current Period		Cumulative Period	
	2020 RM'000	2019 RM'000	2020 RM'000	2019 RM'000
Revenue	819,921	786,108	819,921	786,108
Cost of sales	(721,589)	(687,811)	(721,589)	(687,811)
Gross profit	98,332	98,297	98,332	98,297
Other income	295	362	295	362
Operating expenses	(58,321)	(59,007)	(58,321)	(59,007)
Finance costs	(9,613)	(9,642)	(9,613)	(9,642)
Interest income	187	233	187	233
Profit before zakat and taxation	30,880	30,243	30,880	30,243
Zakat	(4)	(28)	(4)	(28)
Taxation	(8,461)	(10,567)	(8,461)	(10,567)
Profit for the period	22,415	19,648	22,415	19,648
Profit for the period attributable to:				
Owners of the parent	22,399	19,617	22,399	19,617
Non-controlling interests	16	31	16	31
Profit for the period	22,415	19,648	22,415	19,648
Earnings per share - sen				
- Basic	8.57	7.53	8.57	7.53
- Diluted	8.54	7.51	8.54	7.51

The Unaudited Condensed Consolidated Statement of Profit or Loss should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.

Pharmaniaga Berhad (199801011581 (467709-M))

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the quarter ended 31 March 2020	Current Period		Cumulative Period	
	2020	2019	2020	2019
	RM'000	RM'000	RM'000	RM'000
Profit for the period	22,415	19,648	22,415	19,648
<u>Other comprehensive loss, net of tax</u>				
Items that may be subsequently reclassified to profit or loss				
Foreign currency translation loss of foreign operations	(12,520)	(779)	(12,520)	(779)
	(12,520)	(779)	(12,520)	(779)
Total comprehensive income for the period	9,895	18,869	9,895	18,869
Attributable to:				
Owners of the parent	11,626	18,995	11,626	18,995
Non-controlling interests	(1,731)	(126)	(1,731)	(126)
Total comprehensive income for the period	9,895	18,869	9,895	18,869

The Unaudited Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	As at 31 March 2020	As at 31 December 2019
	RM'000	RM'000
ASSETS		
Non-current assets		
Property, plant and equipment	374,646	382,268
Intangible assets	193,812	200,342
Rights-of-use assets	28,619	27,842
Deferred tax assets	48,116	48,139
	<u>645,193</u>	<u>658,591</u>
Current assets		
Inventories	511,961	617,909
Receivables	506,766	267,132
Amount due from immediate holding company	-	14
Tax recoverable	1,265	19,069
Deposits, cash and bank balances	34,230	29,587
	<u>1,054,222</u>	<u>933,711</u>
TOTAL ASSETS	<u>1,699,415</u>	<u>1,592,302</u>
EQUITY AND LIABILITIES		
Equity attributable to equity holders of the Company		
Share capital	151,879	151,879
Reserves	198,096	185,972
Shareholders' equity	<u>349,975</u>	<u>337,851</u>
Non-controlling interests	17,344	19,075
Total equity	<u>367,319</u>	<u>356,926</u>
Non-current liabilities		
Borrowings	463	316
Lease liabilities	2,892	2,125
Deferred tax liabilities	15,096	18,066
Provision for defined benefit plan	9,145	9,999
Government grants	4,205	4,289
	<u>31,801</u>	<u>34,795</u>
Current liabilities		
Payables	650,174	626,510
Amount due to immediate holding company	70	190
Current tax liabilities	1,108	715
Contract liabilities	6,474	6,387
Government grants	341	341
Borrowings	640,435	564,981
Lease liabilities	1,693	1,457
	<u>1,300,295</u>	<u>1,200,581</u>
Total liabilities	<u>1,332,096</u>	<u>1,235,376</u>
TOTAL EQUITY AND LIABILITIES	<u>1,699,415</u>	<u>1,592,302</u>

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the period ended 31 March 2020	Attributable to shareholders of the Company						Non-controlling Interests	Total Equity
	<----- Non-distributable ----->			Distributable		Total		
	Share Capital	Exchange Reserve	Share Reserve	Retained Earnings				
RM'000	RM'000	RM'000	RM'000	RM'000	RM'000			
At 1 January 2020	151,879	3,289	7,191	175,492	337,851	19,075	356,926	
- Net profit for the financial period	-	-	-	22,399	22,399	16	22,415	
- Other comprehensive loss	-	(10,773)	-	-	(10,773)	(1,747)	(12,520)	
Total comprehensive (loss)/income for the financial period	-	(10,773)	-	22,399	11,626	(1,731)	9,895	
Transactions with owners								
Share options granted under Share Option Plan	-	-	68	-	68	-	68	
Shares granted under Long Term Incentive Plan	-	-	430	-	430	-	430	
Total transactions with owners for the financial period	-	-	498	-	498	-	498	
At 31 March 2020	151,879	(7,484)	7,689	197,891	349,975	17,344	367,319	
At 1 January 2019	149,401	1,036	8,015	350,884	509,336	19,327	528,663	
- Net profit for the financial period	-	-	-	19,617	19,617	31	19,648	
- Other comprehensive loss	-	(622)	-	-	(622)	(157)	(779)	
Total comprehensive (loss)/income for the financial period	-	(622)	-	19,617	18,995	(126)	18,869	
Transactions with owners								
Share options granted under Share Option Plan	-	-	200	-	200	-	200	
Shares granted under Long Term Incentive Plan	-	-	442	-	442	-	442	
Total transactions with owners for the financial period	-	-	642	-	642	-	642	
At 31 March 2019	149,401	414	8,657	370,501	528,973	19,201	548,174	

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the period ended 31 March 2020

	2020	2019
	RM'000	RM'000
Operating Activities		
Cash receipts from customers	564,012	669,842
Cash payments to suppliers and employees	(650,558)	(595,552)
Net cash (used in)/generated from operations	(86,546)	74,290
Interest paid	(8,412)	(9,078)
Tax refunded/(paid)	12,983	(3,470)
Zakat paid	(4)	(28)
Interest received	23	29
Net cash (used in)/generated from operating activities	(81,956)	61,743
Investing Activities		
Purchase of property, plant and equipment	(3,119)	(1,967)
Purchase of intangible assets	(2,514)	(9,076)
Proceeds from disposal of property, plant and equipment	1	9
Net cash used in investing activities	(5,632)	(11,034)
Financing Activities		
Dividends paid to owners of the Company	-	(13,025)
Net drawdown/(repayment) of borrowings	95,613	(29,386)
Net cash generated from/(used in) financing activities	95,613	(42,411)
Net increase in cash and cash equivalents	8,025	8,298
Effects of exchange rate changes	(1,579)	(16)
Cash and cash equivalent at beginning of period	22,950	30,826
Cash and cash equivalent at end of period	29,396	39,108
Analysis of cash and cash equivalents:		
Cash and bank balances	27,496	29,748
Deposits with licensed banks	6,734	14,189
	34,230	43,937
less: Deposits maturing more than three (3) months	(4,834)	(4,829)
	29,396	39,108

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Part A - Explanatory Notes Pursuant to Malaysian Financial Reporting Standard 134 ("MFRS 134")

A1. Basis of Preparation

These unaudited condensed consolidated interim financial statements for the period ended 31 March 2020 have been prepared in accordance with MFRS 134 Interim Financial Reporting, IAS 34 Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Malaysia").

These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements for the financial year ended 31 December 2019. The explanatory notes attached to these condensed consolidated interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the year ended 31 December 2019.

A2. Significant Accounting Policies

The significant accounting policies adopted are consistent with those of the audited financial statements for the year ended 31 December 2019, except for the adoption of the following new published standard and amendments to published standards that are effective for the Group's financial year beginning on or after 1 January 2020.

A2.1 Standards and amendments to published standards that are effective

On 1 January 2020, the Group applied the following new published standard and amendments to published standards:

- The Conceptual Framework for Financial Reporting (Revised 2018).
- Amendments to MFRS 101 "Presentation of Financial Statements" and Amendments to MFRS 108 "Accounting Policies, Changes in Accounting Estimates, and Errors".
- Amendments to MFRS 9 "Financial Instruments", MFRS 139 "Financial Instruments: Recognition and Measurement" and MFRS 7 "Financial Instruments: Disclosures".

The adoption of the above amendments to published standards did not have any significant impact on the current period or any prior period and is not likely to affect future periods.

A2.2 Amendments that have been issued but not yet effective

The effective date for the amendments to MFRS 10 "Consolidated Financial Statements" and MFRS 128 "Investments in Associates and Joint Ventures" – Sale or Contribution of Assets between Investor and its Associate or Joint Venture has been deferred to a date to be determined by Malaysian Accounting Standards Board.

The Group is assessing the impact of the above amendments to published standards on the financial statements of the Group in the year of initial adoption.

A3. Audit report in respect of the 2019 financial statements

The audit report on the Group's financial statements for the financial year ended 31 December 2019 was unqualified.

A4. Seasonal or cyclical factors

The Group's operations are not subject to any significant seasonal or cyclical factors.

A5. Unusual items due to their nature, size or incidence

There were no unusual items affecting assets, liabilities, equity, net income, or cash flows during the period under review.

A6. Change in Estimates

There were no material changes in estimates of amounts reported in the current financial period.

In previous year, the Group received a letter from the Ministry of Health ("MOH"), extending its services for the provision of medicines and medical supplies to MOH facilities for an interim period of twenty-five (25) months, commencing 1 December 2019 to 31 December 2021 to allow MOH to make necessary preparations to undertake the service. In addition, the Group also secured a five (5) year contract to continue providing logistics and distribution services for MOH for a period of five (5) years ending 31 December 2024. Following the new contract arrangement, the Group revised the useful life of rights to supply and hence, the remaining unamortised rights to supply was fully recognised in previous year. The revision had been accounted for as a change in accounting estimate and as a result, the amortisation charged in previous financial year was RM247 million.

A7. Debt and equity securities

The Group did not undertake any issuance and/or repayment of debt and equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares in the current financial period.

A8. Dividends

For the first quarter, the Directors have declared a first interim dividend of 6.0 sen (2019: 6.0 sen) per share in respect of the financial year ending 31 December 2020. The dividend will be paid on 30 June 2020 to shareholders registered in the Register of Members at the close of business on 3 June 2020.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT'D)

A9. Operating segments

Operating segments information for the period is as follows:

RM'000	Logistics and distribution	Manufacturing	Indonesia	Unallocated corporate expenses	Eliminations	Total
2020						
Revenue						
External revenue	579,897	836	239,188	-	-	819,921
Inter-segment revenue	-	67,360	-	-	(67,360)	-
Total revenue	579,897	68,196	239,188	-	(67,360)	819,921
Results						
Earnings before interest, taxation, depreciation and amortisation	29,370	14,613	6,701	(1,201)	-	49,483
Depreciation and amortisation	(2,567)	(4,867)	(1,743)	-	-	(9,177)
Finance costs	(3,961)	(824)	(4,995)	-	167	(9,613)
Interest income	203	148	3	-	(167)	187
Profit/(Loss) before zakat and taxation	23,045	9,070	(34)	(1,201)	-	30,880
Zakat	(4)	-	-	-	-	(4)
Taxation	(5,611)	(2,311)	(539)	-	-	(8,461)
Profit/(Loss) for the period	17,430	6,759	(573)	(1,201)	-	22,415
Timing of revenue recognition						
Goods or services transferred:						
- At a point in time	579,312	68,196	239,188	-	(67,360)	819,336
- Over time	585	-	-	-	-	585
	579,897	68,196	239,188	-	(67,360)	819,921
2019						
Revenue						
External revenue	582,604	4,578	198,926	-	-	786,108
Inter-segment revenue	-	69,554	-	-	(69,554)	-
Total revenue	582,604	74,132	198,926	-	(69,554)	786,108
Results						
Earnings before interest, taxation, depreciation and amortisation	25,974	25,425	5,858	(1,789)	-	55,468
Depreciation and amortisation	(8,782)	(5,274)	(1,760)	-	-	(15,816)
Finance costs	(4,923)	(1,220)	(3,741)	-	242	(9,642)
Interest income	332	133	10	-	(242)	233
Profit before zakat and taxation	12,601	19,064	367	(1,789)	-	30,243
Zakat	(28)	-	-	-	-	(28)
Taxation	(5,402)	(4,430)	(735)	-	-	(10,567)
Profit/(Loss) for the period	7,171	14,634	(368)	(1,789)	-	19,648
Timing of revenue recognition						
Goods or services transferred:						
- At a point in time	580,583	74,132	198,926	-	(69,554)	784,087
- Over time	2,021	-	-	-	-	2,021
	582,604	74,132	198,926	-	(69,554)	786,108

For Indonesia segment, the breakdown of segment revenue and results that is denominated in foreign currency and the currency exchange ratio used are as follows:

	Period Ended 31 March					
	2020			2019		
	IDR'000	Exchange	RM'000	IDR'000	Exchange	RM'000
Revenue	814,520,039	0.0294	239,188	698,485,410	0.0285	198,926
Earnings before interest, taxation, depreciation and amortisation	22,819,283	0.0294	6,701	20,569,094	0.0285	5,858

A10. Carrying Amount of Revalued Assets

There has been no revaluation of property, plant and equipment during the current financial period.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT'D)**A11. Subsequent Event**

There was no subsequent event as at 19 May 2020 that will materially affect the financial statements of the financial period under review.

A12. Changes in the Composition of the Group

There were no changes in the composition of the Group for the financial period ended 31 March 2020.

A13. Contingent Liabilities

There is no other contingent liability has arisen since the financial year end.

A14. Commitments

The Group has the following commitments as at 31 March 2020:

	Authorised and contracted for RM'000	Authorised but not contracted for RM'000	Total RM'000
Property, plant and equipment	3,176	116,473	119,649

A15. Financial Risk Management

All aspects of the Group's financial risk management objectives and policies are consistent with those disclosed in the audited financial statements as at and for year ended 31 December 2019.

A16. Intangible Assets

RM'000	Goodwill	Software	Capitalised development cost of work-in- progress	Manufacturing licence and trade name	Rights to supply	Intellectual property	Total
Cost							
At 1 January 2020	145,436	23,682	38,604	21,041	342,865	3,071	574,699
Additions	-	-	1,057	-	-	-	1,057
Transfer from property, plant and equipment	-	-	78	-	-	-	78
Foreign exchange adjustments	(5,779)	(456)	-	(2,136)	-	-	(8,371)
At 31 March 2020	139,657	23,226	39,739	18,905	342,865	3,071	567,463
Accumulated amortisation							
At 1 January 2020	-	6,516	352	11,373	342,865	598	361,704
Amortisation charged	-	326	44	570	-	51	991
Foreign exchange adjustments	-	(456)	-	(1,241)	-	-	(1,697)
At 31 March 2020	-	6,386	396	10,702	342,865	649	360,998
Accumulated impairment							
At 1 January/ 31 March 2020	12,653	-	-	-	-	-	12,653
Net carrying value							
At 31 March 2020	127,004	16,840	39,343	8,203	-	2,422	193,812
At 31 December 2019	132,783	17,166	38,252	9,668	-	2,473	200,342

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT'D)

B17. Performance Review

	Current Period			Cumulative Period		
	2020 RM'000	2019 RM'000	+ /(-) %	2020 RM'000	2019 RM'000	+ /(-) %
Revenue	819,921	786,108	4.3%	819,921	786,108	4.3%
Earnings before interest, taxation, depreciation and amortisation	49,483	55,468	-10.8%	49,483	55,468	-10.8%
Profit before interest, zakat and taxation	40,306	39,652	1.6%	40,306	39,652	1.6%
Profit before zakat and taxation	30,880	30,243	2.1%	30,880	30,243	2.1%
Profit for the period	22,415	19,648	14.1%	22,415	19,648	14.1%
Profit attributable to owners of the parent	22,399	19,617	14.2%	22,399	19,617	14.2%

Quarter 1 2020 vs Quarter 1 2019

For the first quarter ended 31 March 2020, the Group delivered an improved revenue of RM820 million, up by 4.3% compared with RM786 million in the previous year's corresponding quarter. This was primarily due to stronger demand from the Indonesia Division. The Group registered a profit before zakat and taxation (PBT) of RM31 million, reflecting a growth of 2.1% compared with last year's corresponding quarter.

Accordingly, profit after tax (PAT) for the quarter under review grew by 14.1% to RM22 million, compared with RM20 million in the same quarter last year.

The **Logistics and Distribution Division** turned in a higher PBT of RM23 million, up by 82.9% compared with RM13 million in the same quarter last year, driven by stronger contributions from Government hospitals as well as lower operating costs.

The **Manufacturing Division** posted a PBT of RM9 million on the back of a revenue of RM68 million, in line with order trends from Government hospitals. The Division continues to hold positive prospects, propelled by launches of new products and ongoing international expansion, coupled with increased capacity utilisation via its contract manufacturing business.

The **Indonesia Division** recorded a deficit of RM0.03 million. This was mainly attributable to higher finance costs, as well as a delay in payments by government hospitals which is currently affecting Indonesia's healthcare industry.

Consolidated Statement of Financial Position

As at 31 March 2020, the increased receivables was in tandem with higher sales achieved during the first quarter.

Consolidated Statement of Cash Flows

For the period under review, the reduced collections have contributed to the negative operating cash flows.

B18. Material Changes in Quarterly Results Compared to The Results of the Immediate Preceding Quarter

	Current Period	Immediate Preceding Period	+ /(-) %
	2020 RM'000	2019 RM'000	
Revenue	819,921	715,683	14.6%
Earnings before interest, taxation, depreciation and amortisation	49,483	6,143	> 100%
Profit/(Loss) before interest, zakat and taxation	40,306	(229,810)	> 100%
Profit/(Loss) before zakat and taxation	30,880	(238,474)	> 100%
Profit/(Loss) for the period	22,415	(178,733)	> 100%
Profit/(Loss) attributable to owners of the parent	22,399	(178,598)	> 100%

In comparison with the immediate preceding quarter, the Group's revenue increased significantly to RM820 million for the first quarter. This was primarily attributable to stronger demand from Government and private hospitals in Malaysia and Indonesia. This saw the Group post a PBT of RM31 million compared with a deficit of RM238 million in the immediate preceding quarter. The loss in the immediate preceding quarter was due to the revision in useful life of the rights to supply and provision of stock write-off as a result of the voluntary Ranitidine product recall.

Accordingly, PAT for the quarter under review increased to RM22 million, compared with a deficit of RM179 million in the immediate preceding quarter.

B19. Prospects

Despite a tough backdrop, the Group was able to deliver solid results in the first quarter of the year. Nevertheless, the challenging environment is expected to persist as the Covid-19 pandemic continues across the globe. As the healthcare sector does its utmost to prevent the further spread of this virus, the various economic stimulus packages and Covid-19 related initiatives announced by the Government will help to address the needs of healthcare practitioners, providing much-needed funds and support.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT'D)**B19. Prospects (continued)**

As a leading pharmaceutical manufacturer, Pharmaniaga is conscious of its role during this critical time. The Group is dedicated to fulfilling its contract with the Ministry of Health (MOH) for the provision of medicines and medical supplies to MOH facilities, as well as logistics and distribution services to MOH. In tandem with this, to ensure sustainable growth, the Group continues to enhance manufacturing and operational efficiencies and expand its research and development capabilities to explore new avenues to grow its business, including for its Indonesian operations.

B20. Notes on variance in actual profit and shortfall in profit guarantee

The disclosure requirements for explanatory notes for the variance of actual profit after tax and non-controlling interest and shortfall in profit guarantee are not applicable.

B21. Income Tax

	Current Period		Cumulative Period	
	2020 RM'000	2019 RM'000	2020 RM'000	2019 RM'000
Taxation based on profit for the period:				
- Current	8,179	4,516	8,179	4,516
- Deferred	1,479	6,107	1,479	6,107
	9,658	10,623	9,658	10,623
(Over)/Under provision in prior years:				
- Current	(184)	(341)	(184)	(341)
- Deferred	(1,013)	285	(1,013)	285
	(1,197)	(56)	(1,197)	(56)
	8,461	10,567	8,461	10,567

The Group's effective tax rate is higher than the statutory tax rate of 24% principally due to losses of certain subsidiaries.

B22. Corporate Proposal

The disclosure requirements for corporate proposal is not applicable.

B23. Borrowings and Debt Securities - Unsecured

	31 March 2020 RM'000	31 March 2019 RM'000	31 December 2019 RM'000
Non-current:			
Hire purchase:			
- Denominated in Ringgit Malaysia	365	12	187
- Denominated in Indonesian Rupiah	98	53	129
	463	65	316
Current:			
Bankers' acceptances:			
- Denominated in Ringgit Malaysia	276,208	203,013	254,134
- Denominated in Indonesian Rupiah	153,817	153,896	158,679
Revolving credits	210,000	255,000	150,000
Hire purchase:			
- Denominated in Ringgit Malaysia	294	231	219
- Denominated in Indonesian Rupiah	116	84	146
Bank overdraft - denominated in Indonesian Rupiah	-	-	1,803
	640,435	612,224	564,981
The amount of borrowings denominated in Indonesian Rupiah	IDR'000	583,450,758	536,700,348
Exchange rate for Indonesian Rupiah	RM	0.0264	0.0287
			0.0295

As at 31 March 2020, the increased borrowings are primarily due to reduced collections from customers.

As at 31 March 2020, the weighted average floating interest rate of borrowings is 5.4% (2018: 5.6%) per annum.

For borrowings denominated in foreign currency, there is no hedging as the amounts are due within 12 months.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONT'D)**B24. Additional Disclosures**

The Group's profit before zakat and taxation is stated after charging/(crediting) the following:

	Current Period		Cumulative Period	
	2020 RM'000	2019 RM'000	2020 RM'000	2019 RM'000
Depreciation and amortisation	9,177	15,816	9,177	15,816
Net impairment of and write off of receivables	491	470	491	470
Net provision for stock obsolescence and write off of inventories	3,229	1,028	3,229	1,028
Net foreign exchange losses	349	29	349	29

Other than the items mentioned above which have been included in the consolidated statement of profit or loss and consolidated statement of comprehensive income, there were no impairment of assets, gain or loss on derivatives, gain or loss on disposal of subsidiaries and exceptional items included in the results for the period ended 31 March 2020.

B25. Profit Forecast

No commentary is made on any variance between actual profit from forecast profit, as it does not apply to the Group.

B26. Earnings Per Share ("EPS")

(a) Basic earnings per share

	Current Period		Cumulative Period	
	2020	2019	2020	2019
Profit attributable to owners of the Company (RM'000)	22,399	19,617	22,399	19,617
Average number of ordinary shares in issue ('000)	261,230	260,505	261,230	260,505
Basic earnings per share (sen)	8.57	7.53	8.57	7.53

(b) Diluted earnings per share

Profit attributable to owners of the Company (RM'000)	22,399	19,617	22,399	19,617
Average number of ordinary shares in issue ('000)	261,230	260,505	261,230	260,505
Assumed shares issued under Long Term Incentive Plan ('000)	916	641	916	641
Weighted average number of ordinary shares in issue ('000)	262,146	261,146	262,146	261,146
Diluted earnings per share (sen)	8.54	7.51	8.54	7.51

B27. Authorised for Issue

The interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 19 May 2020.

By Order of the Board

Kuala Lumpur
19 May 2020

WAN INTAN IDURA WAN ISMAIL (LS 0010452)
SYARUZAIMI BIN YUSOF (LS 0010451)
Company Secretaries